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ABSTRACT
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current 
used methods lack specificity. In addition, identification of PCa biomarkers that can 
classify patients into high- and low-risk groups for disease progression at early stage 
will improve treatment decision-making. Here, we describe a set of protein-combination 
panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and 
immunoblotting techniques that improve early non-invasive detection and stratification 
of PCa patients.We report a two-protein combination in urinary EVs that classifies 
benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to 
significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-
PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry 
assays in tissue microarrays (TMAs) confirming a strong link between the urinary 
EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance 
yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. 
These results suggest that the proteins identified in urinary EVs distinguishing high- 
and low grade PCa are a reflection of histological changes that may be a consequence 
of their functional involvement in PCa development. In conclusion, our study resulted 
in the identification of protein-combination panels present in urinary EVs that exhibit 
high sensitivity and specificity for PCa detection and patient stratification. Moreover, 
our study highlights the potential of targeted proteomic approaches–such as selected 
reaction monitoring (SRM)–as diagnostic assay for liquid biopsies via urinary EVs to 
improve diagnosis and prognosis of suspected PCa patients.
                  Research Paper
Oncotarget4961www.impactjournals.com/oncotarget
INTRODUCTION
Prostate cancer (PCa) is the most frequently 
diagnosed cancer and the second leading cause of cancer 
related death among men in developed countries [1]. 
Nevertheless, the currently used diagnostic methods for 
PCa detection are far from ideal. Both, prostate-specific 
antigen (PSA) serum measurement, and digital rectal 
examination (DRE) present a low specificity. As a result, 
a significant rate of unnecessary prostate biopsies (PB) is 
practiced [2]. There is therefore still a clear need for new 
biomarkers for a fast and reliable diagnosis of PCa.
Because of the prostate location in the body, in 
direct contact with the urethra, prostate (cancer) secrete 
products can be detected in urine. Consequently, urine 
has been intensively studied as a liquid biopsy source 
of biomarkers for PCa [3–6]. However, the low protein 
concentration, the presence of salts and the vast dynamic 
range of protein expression in urine turn it into a 
particularly complicated fluid for the discovery of protein-
based biomarkers [7].
A rich source for prostate-derived products in 
urine are extracellular vesicles (EVs) such as exosomes, 
50-150 nm sized membrane vesicles that are shed 
by many mammalian cell types, including malignant 
cells and formed within the endosomal network and 
released upon fusion of multi-vesicular bodies with the 
plasma membrane [8]. In the past decade, EVs have 
been recognized as potent vehicles of intercellular 
communication, both in prokaryotes and eukaryotes. This 
is due to their capacity to transfer proteins, lipids and 
nucleic acids, thereby influencing various physiological 
and pathological functions of both, recipient and parent 
cells [8]. Consequently they have been pointed out as a 
promising easily accessible biomarker reservoir, as their 
content (such as proteins, lipids, DNA, and RNA) is 
thought to reflect the molecular composition of their tissue 
of origin [9–11]. The potential of using EVs as source of 
PCa biomarkers as a strategy to overcome the dynamic 
range challenge in urine has generated considerable 
interest in the last years. When EVs are purified from 
the whole urine sample, their protein content is highly 
enriched while at the same time high-abundance soluble 
proteins are removed, enhancing the detectability of low-
abundance proteins [12, 13]. The analysis of the content 
of EVs harvested from urine appears to have important 
advantages such as i) urine collection is a non-invasive 
procedure, ii) the proteomic and genomic material within 
EVs is protected from enzyme degradation by the vesicles 
lipid bilayer [14], and iii) EVs are stable after long-term 
storage at -80°C, which makes prospective studies feasible 
[13].
One of the most significant challenges involving 
the use of EVs for the discovery of new biomarkers is 
the lack of standardized and reliable isolation methods. 
The isolation of exosomes from biological fluids is 
rather complex, due to the presence of protein aggregates 
and other types of vesicles (such as microvesicles and 
apoptotic bodies), which are frequently co-isolated with 
the population of interest [15]. Accordingly, the best 
procedure for EVs purification remains a discussion 
topic in the field, with ultracentrifugation being the most 
frequently used method [16, 17].
Nevertheless, previous reports have indicated 
urinary EVs to be an excellent source of PCa protein 
biomarkers. In 2009, Mitchell et al. analyzed the 
proteomic content of urinary EVs from 10 healthy donors 
and 10 PCa patients who were undergoing hormonal 
therapy prior to radical radiotherapy. In this cohort, PSA 
and Prostate-Specific Membrane Antigen (PSMA) were 
found to be present in almost all of the PCa specimens, 
but not in the healthy donor specimens [18]. A later study 
characterized EVs preparations in pooled post-DRE urine 
samples using a shotgun proteomics procedure identifying 
around 900 proteins [19, 20]. Since then, several studies 
have emerged to determine the role of extracellular 
vesicles in urological malignancies [21–23].
In our study, we used a targeted proteomics 
approach to specifically quantify a set of 64 proteins in 
urinary EVs in the context of PCa biomarker validation in 
a cohort of 107 individual urine-derived human samples. 
Our study resulted in the identification of a protein 
biomarker combination present in urinary EVs that 
exhibits better sensitivity and specificity than the currently 
available biomarkers used for PCa detection and patient 
stratification. Therefore, the protein combination reported 
here improves the detection and management of PCa, 
avoiding the over-diagnosis and over-treatment associated 
with the currently used screening methods.
RESULTS
In this work we used a targeted proteomics approach 
to specifically quantify a set of 64 proteins in urinary EVs 
in the context of PCa biomarker validation in a cohort of 
107 individual urine-derived human samples. Initially a 
cohort of 107 urine samples was collected after DRE and 
EVs were isolate. We then measured protein abundance 
changes in urinary EVs by SRM, and we built protein-
based panels for PCa diagnosis and prognosis in urinary 
EVs, which we also checked in tissue microarrays 
analysis.
EVs isolation from post-DRE urine samples
Several approaches were followed in order to 
assess the purity of the isolated urinary EVs. Urine EVs 
were observed using a transmission electron microscope 
(TEM). The TEM images showed vesicles of the expected 
size, presenting the cup-shaped morphology typical 
of EVs (Figure 1A) [24]. In addition, NTA and protein 
quantification data for all samples (n=107) were used 
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to assess the protocol performance. A linear regression 
analysis showed a good correlation (r=0.85 with p<0.001) 
between the number of vesicles and total amount of protein 
extracted, thus indicating that at least an important part of 
the protein content in the EVs pellet did indeed belong to 
the vesicles quantified by NTA (Figure 1B). Finally, the 
presence of known EVs markers, such as TSG101 (tumor 
susceptibility gene 101), CD81 or Rab5, was confirmed by 
Western blot (Figure 1C).
Validation of protein abundance changes in 
urinary EVs by SRM
The 107 urine samples collected after DRE were 
divided into two groups: PCa patient samples (n=53), 
which include 22 low-grade PCa (Gleason score ≤ 7 
(3+4)) and 31 high-grade PCa (Gleason score ≥ 7 (4+3)); 
and control samples (n=54).
A total of 64 protein candidate biomarkers were 
selected for quantitation by SRM (Supplementary Table 
ST1). One proteotypic peptide was selected per protein 
and a scheduled-SRM method was used to allow the 
monitoring of all 64 proteins in one single run. To ensure 
that the selected peptides correctly represented the true 
fold-changes of the targeted proteins, we used a previously 
in-house shotgun dataset to identify quantotypic peptides 
for the selected proteins (see Methods section). As a result 
of these SRM experiments, we observed that 14 out of 
the 64 initial proteins exhibited a significant different 
abundance between benign and PCa samples (Table 1), 
of which 11 had higher protein levels in urine EVs of PCa 
patients while 3 showed higher levels in urine EVs of 
control patients. Interestingly, when low- and high-grade 
PCa samples were compared, 45 out of the 64 measured 
proteins showed significantly different abundance levels 
(Table 2), with all proteins exhibiting higher levels in low-
grade patients (44 proteins).
To evaluate whether the proteins that were 
significantly changing in abundance as found by SRM-
proteomics could be validated by an independent 
method (Figure 2A-2B), we performed antibody-based 
immunoblotting in a subset of urinary EVs samples from 
the same cohort of patients. Among the known EVs 
markers such as CD9, TSG101 or CD63, protein CD81 
was used as an EVs-related marker in our study. Although 
these are generally accepted by the scientific community 
as proteins commonly found in EVs [25], they have been 
found to present different abundance levels in the presence 
of disease [11]. The results obtained were in agreement 
with the protein quantitation obtained by SRM (Figure 
2C-2D).
Protein-based panels for PCa diagnosis and 
prognosis in urinary EVs
Individual ROC curves and the AUC values were 
calculated for each individual quantified protein. Previous 
studies described that combining multiple proteins might 
improve the diagnostic performance over the use of single 
biomarkers, as single markers may not necessarily reflect 
the multifactorial nature of PCa neither have the necessary 
prediction power for patient classification [26]. Therefore, 
in order to compute a protein combination with better 
diagnostic power we fitted abundances of differentially 
expressed proteins (Figure 3A–3B) into a logistic 
regression model and checked the AUC for each protein 
combination. We identified a protein combination formed 
by TGM4 and ADSV (Figure 3C), which had better 
sensitivity and specificity (AUC = 0.65, CI95: 0.55-0.76) 
while the accuracy obtained by each individual protein 
Figure 1: Quality assessment of the EVs isolation process. A. Transmission electron microscopy images of EVs isolated from 
post-DRE urine; B. Linealregression analysis showing a good correlation between the number of EVs counted by NTA and the total 
amount of protein recovered from the same sample; C. Western blot analysis of TSG101, CD81 and Rab5, described in the literature as 
EVs markers, were performed in EVs isolated from post-DRE urine. Benign and PCa samples were pooled to obtain representative and 
sufficient material.
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Table 1: Targeted proteins exhibiting abundance changes in urinary exosomes between PCa patients and benign 
controls
Gene symbol Protein Uniprot accession FDR FC (PCa vs. Benign)
ADSV Adseverin Q9Y6U3 0.002 1.34
GNS N-acetylglucosamine-6-sulfatase P15586 0.002 1.40
TGM4 Transglutaminase-4 P49221 0.002 0.60
CA4 Carbonic anhydrase 4 P22748 0.002 1.40
TSG101 Tumor susceptibility gene 101 protein Q99816 0.011 1.22
VPS28
Vacuolar protein sorting-
associated protein 28 
homolog
Q9UK41 0.011 1.20
SLC44A4 Choline transporter-like 
protein 4
Q53GD3 0.013 1.24
SLC26A4 Pendrin O43511 0.020 1.21
ITGB3 Integrin β3 P05106 0.020 1.22
PRSS8 Prostasin Q16651 0.020 0.83
SDCBP2 Syntenin-2 Q9H190 0.020 1.20
TSPAN9 Tetraspanin-9 O75954 0.022 1.17
ITGAV Integrin αV P06756 0.047 1.20
PPAP Prostatic acid phosphatase P15309 0.047 0.75
Proteins showing significant protein abundance changes in the SRM analysis (adjusted p-value < 0.05) between benign and 
PCa patients are shown. Proteins with higher abundance in PCa are represented by fold change values > 1, while values < 1 
indicate decreased protein levels in PCa. False discovery rate (FDR); fold change (FC).
Table 2: Targeted proteins exhibiting abundance changes in urinary exosomes between high and low-grade patients
Gene symbol Protein Uniprot accession FDR FC (High vs. Low)
PPAP Prostatic acid phosphatase P15309 < 0.001 0.37
PSA Prostate-specific antigen P07288 < 0.001 0.44
CD63 CD63 antigen P08962 < 0.001 0.46
SPHM N-sulphoglucosamine sulphohydrolase P51688 < 0.001 0.45
GLPK5 Putative glycerol 
kinase 5
Q6ZS86 < 0.001 0.47
FAM177A1 Protein FAM177A1 Q8N128 < 0.001 0.46
GLIPR2
Golgi-associated plant 
pathogenesis-related 
protein 1
Q9H4G4 < 0.001 0.50
DNASE1 Deoxyribonuclease-1 P24855 < 0.001 0.54
(Continued )
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Gene symbol Protein Uniprot accession FDR FC (High vs. Low)
STEAP2 Metalloreductase STEAP2 Q8NFT2 < 0.001 0.58
TOLLIP Toll-interacting protein Q9H0E2 < 0.001 0.55
ATP8B1 Phospholipid-
transporting ATPase IC
O43520 < 0.001 0.70
RRAS Ras-related protein R-Ras P10301 < 0.001 0.67
CIB1 Calcium and integrin-
binding protein 1
Q99828 < 0.001 0.69
SLC26A2 Sulfate transporter P50443 < 0.001 0.65
CD82 CD82 antigen P27701 < 0.001 0.73
GALK1 Galactokinase P51570 < 0.001 0.69
TOM1L2 TOM1-like protein 2 Q6ZVM7 < 0.001 0.64
ATP6V0D1 V-type proton ATPase 
subunit d 1
P61421 < 0.001 0.68
TMPRSS2 Transmembrane protease serine 2 O15393 < 0.001 0.65
PPAP2A Lipid phosphate phosphohydrolase 1 O14494 < 0.001 0.57
GNG4CRYZDBNL Drebrin-like protein Q9UJU6 0.001 0.82
RPSA 40S ribosomal protein SA P08865 0.001 0.74
GSS Glutathione synthetase P48637 0.001 0.71
STEAP4 Metalloreductase 
STEAP4
Q687X5 0.002 0.68
PYGL
Glycogen 
phosphorylase, liver 
form
P06737 0.002 0.74
NUDT2
Bis(5'-nucleosyl)-
tetraphosphatase 
[asymmetrical]
P50583 0.002 0.65
TSPAN9 Tetraspanin-9 O75954 0.003 0.80
UBC Polyubiquitin-C P0CG48 0.004 0.73
TMBIM1 Protein lifeguard 3 Q969X1 0.004 0.70
FAM49B Protein FAM49B Q9NUQ9 0.005 0.79
PTPN13
Tyrosine-protein 
phosphatase non-
receptor type 13
Q12923 0.006 0.78
LPAR3 Lysophosphatidic acid 
receptor 3
Q9UBY5 0.007 0.72
DPP3 Dipeptidyl peptidase 3 Q9NY33 0.010 0.73
GNS N-acetylglucosamine-
6-sulfatase
P15586 0.013 0.74
(Continued )
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was low (TGM4 AUC = 0.58; ADSV AUC = 0.58). This 
result evidenced that the combination of two different 
proteins improved the ability to distinguish benign from 
PCa samples.
Next, we also evaluated protein combinations 
that could correctly classify low and high-grade tumors. 
Individual markers such as CD63 (AUC = 0.65), GLPK5 
(AUC = 0.64), PSA (AUC = 0.66), PPAP (AUC = 0.64) 
and SPHM (AUC = 0.61) were among the single-protein 
panels with best sensitivity and specificity. However, it 
was the combination of these five protein abundances that 
rendered the best protein panel to distinguish patients with 
low-grade and high-grade tumors (PPAP + PSA + CD63 + 
SPHM + GLPK5; AUC = 0.70, CI95: 0.56-0.84) (Figure 
3D).
Tissue microarrays analysis for tissue validation 
of PCa biomarkers
The most promising EVs biomarkers found in the 
protein combination models, such as ADSV and TGM4 
(for the benign vs. PCa comparison) and CD63, GLPK5 
and SPHM (for the low-grade vs. high-grade comparison) 
were further evaluated in patient tissues from radical 
prostatectomies using tissue microarrays (TMAs).
In agreement with the expression in urine EVs, 
IHC on prostate TMA-tissues revealed that both PCa 
diagnostic biomarkers, ADSV and TGM4, were also 
altered in terms of protein detection (ADSV p <  0.001; 
TGM4 p <  0.001) when comparing 98 benign prostatic 
tissues versus 136 PCa tissues (Figure 4A–4B). We then 
analyzed the ability of these two proteins to correctly 
classify patients when directly detected in prostate tissue. 
ROC curves for both, ADSV and TGM4, individual 
proteins were generated, obtaining an AUC of 0.81 (CI95: 
0.74-0.88) for TGM4, and an AUC of 0.73 (CI95: 0.65-
0.81) for ADSV (Figure 4C). Additionally, taking into 
account the clinical progression of each patient, we tested 
ADSV and TGM4 as potential prognostic biomarkers and 
assessed their performance in distinguishing between i) 
low- versus high-grade patients (as defined for the urinary 
EVs experiments); ii) groups of patients who presented 
biochemical recurrence (BCR) versus patients who did 
not. The analyses revealed that TGM4 could indeed 
differentiate between the low and high-grade groups with 
high sensitivity and specificity (p <  0.001; AUC = 0.82, 
CI95: 0.71-0.92) (Figure 4D–4E) as well as between 
the BCR versus no BCR groups (p <  0.001; AUC = 
0.80, CI95: 0.69-0.91) (Figure 4F–4G). These results 
suggest that the proteins identified in urinary EVs reflect 
histological changes and may have a functional role in 
PCa development since we also find them altered in PCa 
tissue.
The profile of urinary EVs proteins obtained by 
SRM analysis after comparing low versus high-grade 
PCa patients (CD63, GLPK5 and SPHM), was also 
validated in tissue samples by using TMAs. CD63 was 
detected at significantly different levels in tissue between 
low- versus high-grade PCa patients (p = 0.021), but 
resulted a modest patient classifier (AUC = 0.62, CI95: 
0.51-0.74) (Figure 5A–5C). Similarly, when classifying 
patients with BCR versus patients without BCR, GLPK5 
was able to differentiate between the two groups (p = 
0.013; AUC = 0.64, CI95: 0.54-0.73) (Figure 5D–5F) 
and, furthermore, taking into account only the patients 
of Gleason 7, the patients that had been developed BCR 
showed significantly lower levels of GLPK5 (p = 0.0015) 
(Supplementary Figure SF1). Finally, SPHM did not 
Gene symbol Protein Uniprot accession FDR FC (High vs. Low)
MPI Mannose-6-phosphate isomerase P34949 0.015 0.76
TSG101DPYS Dihydropyrimidinase Q14117 0.021 0.77
PCYT2
Ethanolamine-
phosphate 
cytidylyltransferase
Q99447 0.021 0.80
VTN Vitronectin P04004 0.024 1.31
PDCD6IPVPS26AABHD17C
Alpha/beta hydrolase 
domain-containing 
protein 17C
Q6PCB6 0.031 0.87
ADSV Adseverin Q9Y6U3 0.034 0.81
Proteins showing significant protein abundance changes in the SRM analysis (adjusted p-value < 0.05) between high- and 
low-grade PCa patients are shown. Proteins with higher abundance in high-grade patients are represented by fold change 
values > 1, while values < 1 indicate decreased protein levels in high grade patients (i.e. patients with bad prognosis). False 
discovery rate (FDR); fold change (FC).
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show, neither significant value when comparing low- 
versus high-grade PCa patients, nor when comparing PCa 
patients with and without BCR.
DISCUSSION
Nowadays, there is still a clear clinical need to 
identify new biomarkers that improve the early non-
invasive detection and stratification of PCa patients. 
Within this context, the use of EVs as source of new 
biomarkers is under intense investigation, especially 
because they can be obtained by non-invasive methods 
using urine samples.
Recently, transcriptomic analysis of urinary EVs 
from PCa patients has been carried out with promising 
results for Cadherin 3, which shows a decreased 
abundance in PCa samples as a source of biomarkers [27] 
and the use of microRNAs as markers for this disease 
has also been extensively reported [28]. In this work, we 
have performed targeted proteomics and immunoblotting 
Figure 2: Abundance changes and diagnostic/prognostic evaluation of targeted proteins in urinary EVs. Volcano plots 
represent differentially expressed target proteins in urinary EVs from A. PCa vs. benign patients and B. from high- vs. low-grade patients; 
C. Western blot of TGM4 and ADSV in a selected set of benign and PCa samples; D. Western blot of CD63, SPHM, TSG101 and PSA in 
a selected set of low and high-grade PCa samples. CD81 was used as EVs related marker.
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techniques to address this question. Our results show that 
alterations detected in urinary EVs reflect the protein 
changes in the prostate tissue and highlight the potential 
of SRM targeted proteomics as diagnostic assay for liquid 
biopsies via urinary EVs to improve diagnosis and detect 
PCa patients with a poor prognosis.
PCa diagnosis and prognosis protein-based 
panels in urinary EVs
Current diagnostic techniques for PCa are based on 
a measurement of serum PSA and DRE, but decisive PCa 
diagnosis is based on PB, which is indicated when patients 
present serum PSA above 4 ng/mL. Furthermore, repeat PB 
is indicated for patients who have a prior negative biopsy 
but continue to have an elevated serum PSA or abnormal 
DRE, or as follow-up of previous pathologic diagnoses of 
pre-malignant HGPIN [29]. The lack of specificity of the 
above-mentioned tools urges for the identification of new 
biomarkers using non-invasive methods that improve the 
early diagnosis of PCa. Although different PSA isoforms 
have been analyzed across multiple studies; the AUC 
value of total serum PSA (biomarker used in the clinic) 
has been estimated to be around 0.6 [30].
In our study, a total of 64 previously identified 
candidate biomarkers for PCa in urinary EVs were 
validated in a large cohort of samples (n=107) by SRM. 
Whereas immunological methods like TMA or ELISA 
represent the traditional way of validation, targeted MS-
based approaches like SRM are emerging as additional 
alternatives [31]. In this study, SRM methodology 
was applied in order to facilitate the simultaneous 
quantification of a large number of candidate proteins in a 
large cohort of samples. The presence of several of these 
proteins had already been described in prostate-related 
urinary EVs by others [19], which proved to be good 
candidates as PCa biomarkers.
In terms of diagnosis, our urinary EVs diagnostic 
panel (AUC=0.65) slightly improves the diagnostic 
performance of serum PSA. However, considering the 
promising potential that EVs have shown as a source of 
biomarkers, further studies will be conducted to verify 
Figure 3: Protein-based panels for PCa diagnosis and prognosis. A-B. Scatter plots representing the protein abundance levels of 
selected proteins that are part of diagnostic and prognostic panels, respectively; C-D. ROC curves of protein-based panels for PCa diagnosis 
(ADSV + TGM4) and prognosis (CD63 + GLPK5 + SPHM + PSA + PPAP).
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Figure 4: Assessment of PCa diagnostic biomarkers in tissue microarrays. A. Tissue microarrays images with 
immunohistochemistry results for ADSV and TGM4; B. Scatter plots representing immunohistochemistry scores (IHC) of ADSV and 
TGM4 in benign and PCa FFPE tissue from PCa patients; C. Diagnostic performance represented by a ROC curve of ADSV and TGM4 
individually. Prognostic value of TGM4 represented as IHC score (D) and ROC curve (E) between low vs. high-grade patients. Relation 
between TGM4 and PCa progression is showed as IHC score (F) and ROC curve (G) between patients with and without biochemical 
recurrence (BCR). Values that are significantly different by the Mann-Whitney test from the control group are indicated by p-value < 0.001 
(*** vs. benign; +++ vs. No BCR).
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if this diagnostic panel, in combination with current 
screening tools, could increase the efficiency in detecting 
PCa and avoid unnecessary biopsies.
From a prognosis point of view, controversy 
exists regarding the potential of PSA as a prognostic 
biomarker. Although often serum PSA has higher 
expression in more aggressive PCa patients [32], it 
is often found decreased together with several EVs 
markers, including PSMA, CD9, TSG101, miR-21 
and miR-375 among others. In agreement with these 
observations, we detected decreased PSA levels in 
urinary EVs [18, 33]. The abundance of PSA within 
urinary EVs in combination with the protein abundance 
of four more proteins (CD63, GLPK5, SPHM and 
PAPP) results in an AUC value of 0.70, for detecting 
PCa patients with a poor prognosis. These findings are 
in agreement with a previous report describing that a 
combination of PSA to CD63 or CD9 improves the 
detection of PCa. Whether the decrease in prostate-
related markers is due to a decrease in the quantity of 
prostate secreted EVs number within urine, or a change 
in protein expression profile within prostate (cancer) 
secreted EVs remains to be clarified [34].
Changes in EVs protein abundances reflect 
alterations in prostate tissue
TMAs of PCa patients were used to directly detect 
each selected protein profile and determine if the observed 
protein content in urinary EVs reflected changes in the 
prostate tissue. All patients included in the study presented 
> 7 years of follow up after surgery, therefore, we were 
able to correlate the results not only with the presence of 
the disease and Gleason score but also with their clinical 
progression (BCR after RP).
The protein abundance changes observed in 
urinary EVs of ADSV and TGM4 were validated in 
prostate tissue by IHC analysis and resulted to have even 
a better AUC value. This result suggest that developing 
new techniques to pre-selecting certain subtypes of 
vesicles may lead to better diagnosis performance. 
ADSV, also known as scinderin (SCIN), has been 
implicated in the translocation of secretory vesicles 
directed to be exocytosed [35, 36]. ADSV has been 
found highly expressed in human PCa tissue, and has 
been described to be critical for the proliferation of PCa 
cells [37].
Figure 5: Assessment of aggressive PCa biomarkers in tissue microarrays. A-B. Scatter plots representing immunohistochemistry 
scores (IHC) of CD63, GLPK5 and SPHM in PCa FFPE tissue from low and high-grade PCa patients; C. ROC curve of CD63 biomarker 
performance; D-E. Scatter plots representing IHC scores of CD63, GLPK5 and SPHM in PCa FFPE tissue from patients with and without 
biochemical recurrence (BCR); F. ROC curve of GLPK5 biomarker performance. Significantly different values were assessed by the Mann-
Whitney test and are indicated by *p-value < 0.05.
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In addition, the IHC analysis also identified 
a relationship between TGM4 protein levels and 
Gleason score as well as BCR development decreasing 
significantly in those patients with a poor prognosis. 
TGM4 is a protein almost uniquely expressed in the 
prostate gland [38] and it has been described to be 
down-regulated in PCa tissue [39]. This protein was 
previously measured in urinary secretions from patients 
with extra-capsular or organ-confined PCa. Although its 
diagnostic power was not evaluated, TGM4 was shown to 
be down-regulated in poor prognostic PCa [40]. Despite 
the controversy about the expression of TGM4 in PCa, 
these previous studies combined with our findings may 
indicate a possible role of TGM4 as a tumor suppressor 
gene and, after a further validation in a larger cohort of 
patients, its potential use not only as a PCa diagnostic 
biomarker in urinary EVs, but also to identify the poor 
prognosis patients using biopsies or tissue samples from 
radical prostatectomy. Thus, ADSV and TGM4 appear to 
be promising candidates to be confirmed in future studies 
aimed to establish their possible roles in PCa clinical 
outcome.
The defined prognostic urinary EVs protein 
profile (CD63, GLPK5 and SPHM) was also validated 
by TMA. PSA and PPAP were discarded from the 
TMA study due to extensive previous research already 
available in the literature. PSA is strongly expressed 
in the prostate, both in benign and neoplastic tissue. 
However, IHC staining detected a lower abundance in 
cancer compared to the adjacent benign epithelium, 
which decreased according to less differentiate PCa 
[41–43]. Similarly, PPAP immunoreactivity has also 
been demonstrated to be more intense in the benign 
prostate epithelium and detected at lower levels in 
PCa [41]. These observations are consistent with the 
levels we have detected for these two proteins in the 
urinary EVs. Among the prognostic proteins, it is 
worth mentioning that CD63 is mainly associated 
with membranes of intracellular vesicles, although 
cell surface expression may also be induced. It has 
been shown that prostate basal epithelial cells do not 
express the characteristic CD antigens of secretory 
cells, however the expression levels of CD63 found in 
cancer cells are similar to that of secretory cells [44]. 
Surprisingly, our study revealed that decreased protein 
levels of CD63 in EVs fractions as well as in prostate 
tissue could indicate poor prognosis of PCa. Similar 
results were obtained with GLPK5 (glycerol Kinase 5) 
taking into account the BCR development, however, it 
is worth noting that this protein was able to distinguish 
patients with Gleason score 7 who developed BCR from 
those who did not, therefore, this candidate could be 
useful in predicting tumor behavior in patients with 
uncertain risk of progressing. From a functional point 
of view, further studies will be required to understand 
the role of this protein in PCa development and 
progression.
Urinary EVs as a source of disease biomarkers 
in liquid biopsies
PCa is a clinically heterogeneous and often 
multifocal disease with a clinical outcome difficult 
to predict. Proteomics data give a different level of 
understanding and together with the innovative high-
throughput technologies is a promising way to identify 
Table 3: Clinico-pathological conditions of patients included in the study
SRM experiments (urine) TMAs Validation (FFPE)
Benign PCa Benign PCa
No. of samples 54 53 98 136
Age (yr)* 65.6 (53 - 78) 67.7 (51 - 87) 64 (53-72) 64 (53-73)
Serum PSA (ng/mL)* 8.1 (2.5 - 41.1) 17.3 (1.0 - 245.4) 9,8 (2,5-48) 11 (1,1-66)
No. of vesicles/mL* 5,1*10
12 (5,3*1011- 
2,2*1013)
4,1*1012 (4,6*1011- 
1,4*1013) - -
Total protein (μg/mL)* 1.1 (0.2 - 8.0) 0.8 (0.2 - 4.9) - -
Low Grade (GS ≤ 
7(3+4))
- 22 51 50
High Grade (GS ≥ 
7(4+3)
- 31 48 86
No BCR - - 49 72
BCR - - 49 64
* Values are represented as mean (range); GS (Gleason's Score)
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new biomarkers for PCa detection, prognosis and therapy 
[45]. In this work we combined this strategy with the 
isolation of urinary EVs to identify new protein biomarker 
panels for PCa diagnosis (TGM4 and ADSV) and for 
patient stratification (PSA, PPAP, CD63, GLPK5 and 
SPHM).
The strategy presented in this manuscript 
highlights the potential of liquid biopsies via urinary 
EVs isolation for the diagnosis and PCa stratification, 
and its associated clinical research. Biomarker 
detection from urinary EVs is capable of distinguishing 
aggressive from clinically insignificant PCa and other 
benign conditions beyond serum PSA and, thus, it 
might avoid PCa related over-diagnosis and over-
treatment. Taking all together, we conclude that the 
future of the diagnosis and prognosis in PCa will 
benefit from research of biomarkers in EVs, leading to 
an improvement in therapeutic decision making with 
liquid biopsies.
METHODS
Experimental design and statistical rationale
This is a retrospective case-control study to 
identify biomarkers associated to PCa. The main 
objectives are to assess the potential of urinary EVs as 
a source of PCa biomarkers and to evaluate a different 
biomarker candidates previously identified in a larger 
cohort of patients. The validation cohort was integrated 
by a total of 107 urine samples obtained after DRE 
(Table 3). For statistical analysis, PCa cases were divided 
into low grade PCa (Gleason score ≤ 7(3+4); n=22) and 
high grade PCa (Gleason score ≥ 7(4+3); n=31). The 
control group included patients without PCa (n=54), 
such as patients with benign prostatic hyperplasia (BPH), 
inflammation or high-grade prostatic intraepithelial 
neoplasia (HGPIN).
Patients selection and inclusion criteria
This study obtained approval from the Vall Hebron 
University Hospital (Barcelona, Spain) institutional 
review board (PR(IR)56/2014). Written informed 
consent was obtained from all the study participants 
and samples were coded to ensure sample tracking and 
confidentiality on patient/donor identity. All patients 
were men with suspicion of PCa according to abnormal 
DRE and/or serum PSA levels higher than 4 ng/mL, 
referred for a first PB at the Urology Service of the Vall 
d’Hebron University Hospital (Barcelona, Spain) from 
2008 to 2012. Definitive diagnosis was achieved after 
PB. Patients with a diagnosis of PCa and age matched 
controls were selected. Patients with an unrelated chronic 
or acute severe illness and/or previous PCa therapies 
were excluded from the study.
Urine samples collection and extracellular 
vesicles isolation
Urine was collected after DRE, a procedure included in 
the standard process for detection of PCa. Urine (30-50 mL) 
was collected in urine collection cups, kept on ice, transported 
to the lab and processed within 2 h of its collection. The 
samples were centrifuged at 2,500 g for 10 min at 4 °C and 
the supernatant, containing the EVs, was supplemented with 
a cocktail of protease inhibitors (Sigma-Aldrich, St Louis, 
MO, USA) and stored at –80 °C until its use.
For EVs isolation, cell-free urine samples were first 
centrifuged at 16,500 g, 20 min, to remove larger vesicles 
and any possible remaining cell debris. The pellet from this 
centrifugation was treated with dithiothreitol (DTT) (37 
°C, 10 min) in order to break THP (Tamm-Horsfall protein) 
fibers and release EVs, and centrifuged again at 16,500 g, 
20 min. Supernatants from the two centrifugations were 
mixed together and filtered through a 0.2 μM pore size 
filter. Samples were then ultracentrifuged at 100,000 g 
for 120 min at 4 °C. The resulting pellet was washed with 
PBS (phosphate buffered saline) and centrifuged again at 
100,000 g, 60 min at 4 °C. The final pellet was resuspended 
in 50 μL PBS, of which 5 μL were set aside and stored at 
-80 °C for nanoparticle tracking analysis (NTA) and the 
rest was mixed with 50 μL lysis buffer (Tris 20 mM pH 
8.8, NaCl 150 mM, EDTA 5 mM, Triton X-100 1%, and 
protease inhibitors) and stored at -20 °C until its use.
Transmission electron microscopy
Transmission electron microscopy (TEM) imaging 
of EVs was performed using negative-staining technique. 
Briefly, pellets recovered from the ultracentrifugation, 
containing the EVs, were fixed with 4% paraformaldehyde 
and then deposited on Formvar/Carbon-coated grids, 
which were negatively stained with uranyl acetate. EVs 
preparations were examined using a transmission electron 
microscope JEOL JEM 1010 (Japan Electron Optics 
Laboratory Co., Tokyo, Japan).
Nanoparticle tracking analysis
Vesicles present in purified samples were analyzed by 
NTA using the NanoSight LM14 system (NanoSight Ltd., 
Amesbury, UK), configured with a high sensitivity digital 
camera system (Hamamatsu C11440 ORCA-Flash2.8, 
Hamamatsu City, Japan). Three videos of 60s duration were 
recorded for each sample and average measurements and 
standard deviations were calculated. Videos were analyzed 
using the NTA-software (version 2.3), with the minimal 
expected particle size, minimum track length, and blur set 
to automatic. Camera shutter speed and camera gain were 
set to maximum. Camera sensitivity and detection threshold 
were set close to maximum (15 or 16) and minimum (2 to 
5), respectively, to reveal small particles. Samples were 
diluted in ultrapure water.
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Sample preparation for mass spectrometry
Urinary EVs were disrupted by sonication 
(LABSONIC M, Sartorius Stedim Biotech, Goettingen, 
Germany) at 100 % amplitude for 4 pulses of 5 s each 
separated by 5 s pauses on ice. The extracted proteins 
were stored at –20 °C. An aliquot of each preparation was 
used for protein quantity estimation using the DC Protein 
Assay (Bio-Rad, Bio-Rad Laboratories, Hercules, CA, 
USA), following the manufacturer’s instructions. Samples, 
usually diluted 1:10, were compared in triplicates against 
serially diluted Bovine Serum Albumin (BSA) as standard.
Filter-aided sample preparation (FASP) was 
performed using a 10 kDa molecular weight cut-off filter 
(Merck Millipore) as previously described [46]. Briefly, 
20 μg of sample in RIPA buffer were loaded in the filter 
unit and washed twice with 8 M urea by centrifugation 
at 14,000 g for 15 min. Proteins were reduced with 
10 mM DTT for 1 h at RT, and alkylated with 30 mM 
iodoacetamide (IAA) 30 min in the dark. The reaction was 
stopped with 37.5 mM n-acetylcysteine (NAC) during 15 
min, and the solutions were removed by centrifugation 
at 14,000 g for 15 min. The samples were then washed 
once with 1 M urea. The resulting pellet was diluted with 
40 μL of 1 M urea, containing 20 μg of trypsin, and it 
was incubated overnight 37 °C for protein digestion. 
Finally, tryptic peptides were collected in a clean tube 
by centrifugation at 14,000 g for 10 min, and this filtrate 
was acidified with 0.3-0.5 μL of concentrated formic acid. 
Samples were stored at –20 °C until further analysis.
Selected reaction monitoring
A total of 64 proteins were selected for the targeted 
proteomic analysis based on previous in-house discovery 
proteomics experiments and additional information 
retrieved from the literature. Literature search was focused 
on previous studies in which differentially expressed 
proteins in PCa had been identified using tissue, urine and 
different PCa cell lines as a source of biomarkers [11, 19, 
21, 23].
One quantotypic peptide per protein was selected 
based on a previously in-house shotgun dataset. Briefly, 
to ensure that the selected peptides correctly represented 
the true fold-changes of the targeted proteins, we extracted 
all ion intensity chromatograms from MS1 scans for the 
identified peptide precursors of the selected proteins 
across 24 samples. All the ions were visually inspected 
and area integration of all the precursor ions was manually 
reviewed. The integrated areas were used to statistically 
assess protein fold-changes. Peptides were selected for the 
SRM experiment according the following criteria: i) the 
difference between the protein and the peptide fold-change 
(the lower the better); and ii) the intensity of the peptide 
(the more intense the better). In the case of proteins that 
exhibited not significant abundance changes, peptides 
selection was based on peptide intensity.
All samples were individually digested (see 
above) and one isotopically labeled reference peptide at 
C-terminal lysine (13C
6
,15N2-Lys) or arginine (
13C
6
,15N
4
-
Arg) per protein was spiked into the digested samples 
prior mass spectrometry (MS) acquisition (Supplementary 
Table ST1).
Selected reaction monitoring (SRM) measurements 
were performed with unfractionated samples on a 
hybrid triple quadrupole / ion trap mass spectrometer 
(5500 Q-Trap; AB Sciex Instruments, Foster, CA, USA) 
equipped a reversed-phase chromatography 25-cm column 
with an inner diameter of 75 μm, packed with 1.9-μm C18 
particles (Nikkyo Technos, Tokyo, Japan) and a 2-cm 
pre-column (Acclaim PepMap 100, C18, 15 μm, 100-
A; Dionex, Sunnyvale, CA, USA). Loading buffer: H2O 
+ 0.1% formic acid; Elution buffer: ACN + 0.1% formic 
acid. Flow rate: 250 nL/min. Gradient: From 7 to 40% 
eluting buffer in 60 min. Blank runs were performed 
between the SRM measurements of biological samples 
to avoid sample carryover. Measurements were done in 
scheduled SRM mode, using a SRM detection window of 
300 seconds and a total cycle time of 2.5 seconds. For 
each peptide of interest five transitions were monitored for 
both the endogenous and the isotopically labeled peptides .
Transition groups corresponding to the targeted 
peptides were evaluated with Skyline v2.5 based on 
the correlation of transition intensities between the 
endogenous and reference SRM traces as well as with the 
reference spectral library, on the relative retention times 
across runs, and on the co-elution of endogenous peptide 
and spiked-in references [47]. Transition areas were used 
to calculate protein ratios between the two groups using 
the linear mixed-effects model as implemented in the R 
package MSstats v2.0 [48].
The raw proteomics data have been deposited to the 
ProteomeXchange Consortium [49] via the PASSEL [50] 
partner repository with the dataset identifier PASS00843.
Western blotting
Proteins were separated by 10% SDS-PAGE under 
reducing or non-reducing conditions and transferred 
to PVDF membranes. For blocking, membranes were 
soaked in 5% non-fat dried milk in TBS-Tween20 
(Tris-buffered saline, 0.01% Tween20). Proteins were 
immunodetected using antibodies against TSG101 
(1:500; Abcam, Cambridge, UK), CD81 (1:100; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), CD63 (non-
reduced conditions, 1:1000, Merck Millipore, Germany), 
PSA/KLK3 (1:100, Dako, Denmark), TGM4, ADSV, 
SPHM (1:1000, 1:100, 1:100, Sigma-Aldrich, MO, USA), 
in overnight incubations at 4°C. Afterwards, membranes 
were washed and incubated with a secondary HRP-
coupled antibody (horseradish peroxidase-conjugated 
antibody) for 1h at room temperature. Finally, HRP signal 
was revealed using the Immobilon Western HRP Substrate 
(Merck Millipore, Darmstadt, Germany).
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Tissue microarrays
For the tissue microarrays (TMAs) a total of 165 
samples of radical prostatectomy (RP) were selected 
from patients with > 7 years of clinical follow up. Low 
and high-grade patients and patients with and without 
biochemical recurrence (BCR) were included. BCR is 
defined as the first post-operative PSA value > 0.4 ng/
mL, confirmed by at least 1 subsequent increasing value 
(persistent PSA increase) after undetectable PSA post-
operatively. From each PCa patient, both cancerous and 
benign peripheral tissues were inspected. Formalin-
fixed paraffin-embedded tissue (FFPE) samples of PCa 
available from the archives of the Pathology Department 
of the Vall Hebron University Hospital (Barcelona, 
Spain) were used. Clinico-pathologic features of these 
patients are detailed in Table 1 . For TMA construction, 
a hematoxylin and eosin-stained section was made from 
each block to define representative tumor regions. Tissue 
cylinders with a diameter of 1 mm were then punched 
from selected tumor and non-malignant areas of each 
donor tissue block in triplicates and brought into a 
recipient paraffin block using a custom-made precision 
instrument (Advanced Tissue Arrayer Chemicon 
International USA). Sections (3 μm) of the resulting TMA 
block were obtained with a Leica RM 2255 microtome 
(Finesse ME+ A77500016 microtome, Thermo Scientific) 
and transferred to glass slides and stained with different 
antibodies as described below.
Immunohistochemistry
Slides were incubated at 55°C overnight, then 
treated in xylene to de-paraffinize them, and subsequently 
re-hydrated through graded alcohol rinses. TGM4, ADSV, 
GLPK5, CD63 and SPHM immunohistochemical (IHC) 
staining were performed. Heat-induced antigen retrieval 
was performed by immersing the slides in 10 mM citrate 
buffer (C
8
H
8
O
7
.H2Odd 0.01M + C6H5O7.H2Odd; pH 6.0). 
Nonspecific staining was avoided using 10 % normal-
matched serum and 0.3 % H2O2 in PBS buffer for 30 
min. Antigen was detected by 1 h incubation at room 
temperature or overnight at 4°C with the relevant primary 
antibody (ADSV 1:1000, TGM4 1:1000, GLPK5 1:50, 
SPHM 1:600, Sigma-Aldrich, MO, USA; CD63 1:500, 
Merck Millipore, Germany), followed by an appropriate 
secondary antibody conjugated to a peroxidase complex 
(Envision+ poly-HRP system; DAKO Cytomation, 
Glostrup, Denmark). Color development was done using 
DAB+ Chromogen (DAKO Cytomation) followed by 
counterstaining with hematoxylin. Two-experienced 
pathologist evaluated the staining of the TMA and 
calculated a histoscore based on the percentage of stained 
cells and the intensity of the staining (ranging from 1 
-weakly positive- to 3 -strongly positive). Histoscores 
were calculated from the sum of (1x % cells staining 
weakly positive) + (2x % cells staining moderately 
positive) + (3x % cells staining strongly positive) to a 
maximum of 300.
Statistical analysis of mass spectrometric data
SRM peak areas were normalized based on the areas 
corresponding to the isotopically labeled internal peptide 
references, which were used to first equalize the median 
abundance (log2-areas) for all reference peptides across 
all runs, and then all endogenous peptide areas in a run 
were corrected by a same bias. Comparisons of relative 
protein abundance between groups were performed using 
the MSstats R package [48].
For predictive analysis, the whole patient cohort 
was used. Initially, the quantity of each protein per sample 
was estimated based on a relative log2-transformed using 
the MSstats R package, and these protein quantities were 
then used as input variables to a logistic regression model 
between the tested patient groups. Each protein was fitted 
in the model between two groups and its classification 
ability was evaluated by the area under the curve 
(AUC) obtained in the receiver operating characteristic 
(ROC) curve. AUC was used as it summarizes well the 
classification performance of each protein in terms of 
specificity and sensitivity, with candidates with better 
specificity and sensibility having an AUC value close 
to 1. Additional proteins were iteratively added and 
the variation of AUC was checked and only those that 
increased the AUC value were kept for further iterations 
[51]. The pROC package in R was used to draw ROCs, 
calculate the AUC values and estimate the confidence 
intervals of the ROC curves. Mann-Whitney test and the 
pROC package mentioned above were used for the IHC 
data analysis.
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